Display Settings:

Format

Send to:

Choose Destination
Oncoimmunology. 2012 Aug 1;1(5):756-758.

DKK1 as a novel target for myeloma immunotherapy.

Author information

  • 1Department of Lymphoma/Myeloma; Division of Cancer Medicine; Center for Cancer Immunology Research; The University of Texas MD Anderson Cancer Center; Houston, TX USA.

Abstract

Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 could be developed as a novel vaccine for myeloma immunotherapy.

PMID:
22934273
[PubMed]
PMCID:
PMC3429585
Free PMC Article

Images from this publication.See all images (1)Free text

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk